Bamlanivimab
Catalog No.
BA2281
Bamlanivimab (Anti-HumanSARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in November 2020.
Featured Products
Bamlanivimab (Anti-HumanSARS-CoV-2) was the first COVID-19 monoclonal antibody (mAb) to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in November 2020. Bamlanivimab has been withdrawn in April 2021 as the number of SARS-CoV-2 virus variants resistant to Bamlanivimab increases.
| Physical Appearance | A liquid |
| Storage | -20°C |
| Cas No. | 2423943-37-5 |
| Synonyms | Anti-Human SARS-CoV-2 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |